-
1.发明申请RNA-dependent RNA polymerase functioning preferably on a RNA matrix and promoter-dependent transcription process with said RNA-dependent RNA polymerase 有权优选在RNA基质上起作用的RNA依赖性RNA聚合酶和使用所述RNA依赖性RNA聚合酶的启动子依赖性转录过程公开(公告)号：US20050069933A1
公开(公告)日：2005-03-31
申请号：US10940964
申请日：2004-09-15
申请人： Valerie Cheynet-Sauvion , Nadege Arnaud-Barbe , Guy Oriol , William McAllister , Bernard Mandrand , Francois Mallet
发明人： Valerie Cheynet-Sauvion , Nadege Arnaud-Barbe , Guy Oriol , William McAllister , Bernard Mandrand , Francois Mallet
IPC分类号： C12N15/09 , C12N1/21 , C12N9/12 , C12N15/54 , C12Q1/68 , C07H21/04 , C12N9/22 , C12N15/74 , C12Q1/70
CPC分类号： C12Q1/6865 , C12N9/127 , C12Q2521/119
摘要： RNA may be transcribed using a nucleotide reagent as the promoter. The reagent may enable RNA to be transcribed without sequence specification and without protein cofactors, by means of an RNA polymerase that is known to be DNA-dependent such as the RNA polymerase of the phage T7, or by means of new, mutated RNA polymerase with the ability to synthesize a transcription product of polynucleotide matrix with a higher yield when the matrix is RNA than when the matrix is DNA. This type of RNA polymerase can be obtained by effecting mutations on a coding gene for a wild-type RNA polymerase, and then by selecting the mutated RNA polymerase with the ability. The invention can be applied notably to the detection, synthesis or quantification of RNA.
摘要翻译： 可以使用核苷酸试剂作为启动子来转录RNA。 通过已知DNA依赖性的RNA聚合酶，例如噬菌体T7的RNA聚合酶，或者通过新的突变的RNA聚合酶，使试剂可以使RNA不经序列指定而没有蛋白质辅因子转录， 当基质是RNA时，与基质是DNA相比，合成具有更高收率的多核苷酸基质的转录产物的能力。 可以通过对野生型RNA聚合酶的编码基因进行突变，然后通过选择具有该能力的突变的RNA聚合酶来获得这种类型的RNA聚合酶。 本发明可以应用于RNA的检测，合成或定量。
-
2.发明申请Nucleotide sequence coding for a modified protein of interest, expression vector and method for obtaining same 审中-公开编码目的修饰的蛋白质的核苷酸序列，表达载体及其获得方法公开(公告)号：US20050033019A1
公开(公告)日：2005-02-10
申请号：US10495491
申请日：2002-11-21
IPC分类号： C12N15/09 , C07K14/16 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N11/06 , C12N15/48 , C12P21/02 , C12Q1/68 , C07H21/04 , C07K14/705
CPC分类号： C07K14/005 , C12N11/06 , C12N2740/16222
摘要： The invention concerns a nucleotide sequence coding for a modified protein of interest, said protein of interest having, after purification and immobilization, at least the same biological activity as the native protein of interest and being directly usable, said sequence comprising at least a gene coding for said protein of interest, a nucleotide fragment, called polyK, coding for a succession of at least six lysine residues, and a nucleotide fragment, called polyH, coding for a succession of at least six histidine residues; a vector comprising such a sequence; and a method for obtaining a purifiable and immobilized modified protein of interest.
摘要翻译： 本发明涉及编码目的修饰的蛋白质的核苷酸序列，所述目的蛋白质在纯化和固定后至少具有与目的天然蛋白质相同的生物学活性且可直接使用，所述序列至少包含编码 对于所述感兴趣的蛋白质，编码一系列至少六个赖氨酸残基的称为polyK的核苷酸片段和称为polyH的核苷酸片段，其编码连续至少六个组氨酸残基; 包含这样的序列的载体; 以及获得可纯化和固定的目标改性蛋白质的方法。
-
3.发明申请Peptide Domain Required For Interaction Between The Envelope of a Virus Pertaining to The Herv-W Interference Group and an Hasct Receptor 审中-公开与Herv-W干扰组和Hasct受体有关的病毒信封之间相互作用所需的肽域公开(公告)号：US20090148454A1
公开(公告)日：2009-06-11
申请号：US12087893
申请日：2007-02-09
申请人： Francois Mallet , Guy Oriol , Valerie Cheynet
发明人： Francois Mallet , Guy Oriol , Valerie Cheynet
IPC分类号： A61K39/395 , C07K14/00 , C12N15/11 , C12N15/00 , C12N5/08 , A61K31/7088 , A61K38/16 , C12Q1/70 , C07K16/18 , C12P21/00
CPC分类号： C07K14/005 , A61K38/162 , A61K39/12 , A61K39/21 , C07K16/1036 , C07K2317/34 , C12N7/00 , C12N2740/10022 , C12N2740/10034 , C12N2740/10063 , G01N2333/15
摘要： The invention relates to a peptide domain required for interaction between the envelope of a virus pertaining to the HERV-W interference group and a hASCT receptor, comprising an N end point and a C end point. Said peptide domain is defined, at the N end point thereof, by a pattern formed by the amino acids L (Z)-proline-cysteine-X-cysteine in which Z is any amino acid, is a whole number between 2 and 30, and X is any amino acid, and at the C end point thereof, by a pattern formed by the amino acids serine-aspartic acid-Xa-Xb-Xc-Xd-Xe-aspartic acid-Xf-Xg-(Z) in which Xa, Xb, Xc, Xd, Xe, Xf, Xg are any amino acids, Z is any amino acid, B is a whole number between 15 and 25, preferably 20. The peptide domain comprises, between the N end point and the C end point, at least one pattern selected from the following patterns: a pattern formed by the amino acids cysteine-X2-X3-X4-X5-X6-cysteine in which X2, X3, X4, X5, X6 are any amino acids, and a pattern formed by the amino acids cysteine-X7-X8-X9-X10-X11-X12-X13-X14-X15-cysteine-trytophane in which X7, X8, X9, X10, X11, X12, X13, X14, X15 are any amino acids.
摘要翻译： 本发明涉及涉及HERV-W干扰组的病毒包膜与hASCT受体之间的相互作用所需的肽结构域，其包含N个终点和C个终点。 所述肽结构域在N末端被由氨基酸L（Z） - 脯氨酸 - 半胱氨酸-X-半胱氨酸形成的图案定义，其中Z是任何氨基酸，其整数为2〜30， X为任何氨基酸，C端为氨基酸丝氨酸 - 天冬氨酸-Xa-Xb-Xc-Xd-Xe-天冬氨酸-Xf-Xg-（Z）形成的图案，其中 Xa，Xb，Xc，Xd，Xe，Xf，Xg是任何氨基酸，Z是任何氨基酸，B是15和25之间的整数，优选为20.肽结构域包括N端和C 从以下图案中选择的至少一种图案：由X2，X3，X4，X5，X6是任何氨基酸的氨基酸半胱氨酸-X 2 -X 3 -X 4 -X 5 -X 6半胱氨酸形成的图案，以及 其中X7，X8，X9，X10，X11，X12，X13，X14，X15的氨基酸半胱氨酸-X7-X8-X9-X10-X11-X12-X13-X14-X15-半胱氨酸 - 替硝唑形成的图案是 任何氨基酸。
-
公开(公告)号：USRE39031E1
公开(公告)日：2006-03-21
申请号：US09680946
申请日：2000-10-06
申请人： Francois Mallet , Guy Oriol , Bernard Mandrand
发明人： Francois Mallet , Guy Oriol , Bernard Mandrand
CPC分类号： C12Q1/686 , C12Q2521/107
摘要： An RNA amplification method is particularly useful for diagnosing bacterial or viral infections or genetic disorders and for cell typing. The method includes the steps of denaturing a solution containing RNA, synthesizing a first cDNA strand from a suitable primer in the presence of reverse transcriptase, denaturing the heteroduplex formed, synthesizing a second cDNA strand from a second primer in the presence of DNA polymerase and then subjecting the cDNA formed to a sufficient number of amplification cycles. All the reactants and solvents are first placed in the same container to provide a single manipulation step that avoids the risk of contamination.
摘要翻译： RNA扩增方法特别适用于诊断细菌或病毒感染或遗传疾病和细胞分型。 该方法包括以下步骤：使含有RNA的溶液变性，在逆转录酶存在下合成来自合适引物的第一条cDNA链，使形成的异源双链变性，在DNA聚合酶存在下从第二引物合成第二条cDNA链，然后 使形成的cDNA进行足够数量的扩增循环。 所有的反应物和溶剂首先放在同一容器中，以提供避免污染风险的单一操作步骤。
-
公开(公告)号：US20070260053A1
公开(公告)日：2007-11-08
申请号：US11660952
申请日：2005-09-23
申请人： Francois Mallet , Guy Oriol , Jean-Philippe Pichon
发明人： Francois Mallet , Guy Oriol , Jean-Philippe Pichon
CPC分类号： C12Q1/6865 , C12Q2521/301
摘要： The present invention relates to a method for generating transcripts from: at least one RNA sequence to be amplified comprising a “primer” region and a region of interest, and an amplification primer comprising a promoter region, and a region capable of hybridizing to said “primer” region of the RNA sequence to be amplified, said method being carried out at constant temperature, and comprising the following steps: a) said primer is hybridized with the RNA to be amplified, b) the primer is extended by means of a reverse transcriptase enzymatic activity in order to generate a complementary deoxyribonucleic acid (cDNA) sequence of the RNA to be amplified, c) the RNA to be amplified, hybridized to said cDNA, is cleaved by means of an enzyme that has a ribonuclease H activity, so as to obtain fragments of RNA to be amplified, hybridized to said cDNA, d) the ends of said fragments of RNA to be amplified are extended by means of a reverse transcriptase and strand displacement enzyme, so as to obtain RNA-DNA/DNA hybrids, e) RNA transcripts are obtained from the RNA-DNA/DNA hybrids formed in step d), by means of an enzyme that has an RNA polymerase activity.
摘要翻译： 本发明涉及一种从以下产生转录物的方法：至少一个待扩增的RNA序列，其包含“引物”区和感兴趣区，扩增引物包含启动子区和能与所述“ 引物“区域，所述方法在恒温下进行，并包括以下步骤：a）所述引物与待扩增的RNA杂交，b）引物通过反向扩增 转录酶酶活性，以产生要扩增的RNA的互补脱氧核糖核酸（cDNA）序列，c）通过具有核糖核酸酶H活性的酶将待扩增的与所述cDNA杂交的RNA切割，因此 以获得要扩增的RNA片段，与所述cDNA杂交，d）通过逆转录酶和链置换酶扩增待扩增的所述RNA片段的末端，以便 获得RNA-DNA / DNA杂交体，e）通过具有RNA聚合酶活性的酶从步骤d）中形成的RNA-DNA / DNA杂交体获得RNA转录物。
-
公开(公告)号：US5817465A
公开(公告)日：1998-10-06
申请号：US825617
申请日：1997-03-31
申请人： Francois Mallet , Guy Oriol , Bernard Mandrand
发明人： Francois Mallet , Guy Oriol , Bernard Mandrand
CPC分类号： C12Q1/686 , C12Q1/6865
摘要： An RNA amplification method is particularly useful for diagnosing bacterial or viral infections or genetic disorders and for cell typing. The method includes the steps of denaturing a solution containing RNA, synthesizing a first cDNA strand from a suitable primer in the presence of reverse transcriptase, denaturing the heteroduplex formed, synthesizing a second cDNA strand from a second primer in the presence of DNA polymerase and then subjecting the cDNA formed to a sufficient number of amplification cycles. All the reactants and solvents are first placed in the same container to provide a single manipulation step that avoids the risk of contamination.
-
公开(公告)号：US06184025B2
公开(公告)日：2001-02-06
申请号：US09200990
申请日：1998-11-30
IPC分类号： C12N112
CPC分类号： C07K14/005 , A61K38/00 , C12N7/00 , C12N2740/10021 , C12N2740/10022 , Y10S435/912
摘要： Composition comprising two pathogenic and/or infective agents associated with multiple sclerosis, namely a first agent which consists of a human virus possessing reverse transcriptase activity and related to a family of endogenous retroviral elements, or a variant of said virus, and a second agent, or a variant of said second agent, these two pathogenic and/or infective agents originating from the same viral strain chosen from the strains designated, respectively, POL-2 deposited with the ECACC on Jul. 22, 1992 under Accession Number V92072202 and MS7PG deposited with the ECACC on Jan. 8, 1993 under Accession Number V93010816, and from their variant strains.
摘要翻译： 包含与多发性硬化相关的两种致病和/或感染因子的组合物，即由具有逆转录酶活性并与内源性逆转录病毒元件家族相关的人病毒或所述病毒的变体组成的第一药剂和第二药剂， 或所述第二药剂的变体，这两种源自相同病毒株的两种致病和/或感染剂分别选自1992年7月22日以ECACC保藏的保藏号为V92072202的POL-2和存储的MS7PG的菌株 1993年1月8日，ECACC以保藏号V93010816和其变体菌株。
-
公开(公告)号：US5871745A
公开(公告)日：1999-02-16
申请号：US471969
申请日：1995-06-06
IPC分类号： G01N33/569 , A61K31/70 , A61K35/76 , A61K38/00 , A61K39/21 , A61P25/00 , A61P31/12 , C07H21/04 , C07K7/06 , C07K14/005 , C07K14/15 , C12N5/08 , C12N5/10 , C12N7/00 , C12N15/09 , C12N15/48 , C12Q1/68 , G01N33/68 , C07K1/00
CPC分类号： C07K14/005 , C12N7/00 , A61K38/00 , C12N2740/10021 , C12N2740/10022 , Y10S435/912
摘要： Composition including two pathogenic and/or infective agents associated with multiple sclerosis, namely a first agent which consists of a human virus possessing reverse transcriptase activity and related to a family of endogenous retroviral elements, or a variant of the virus, and a second agent, or a variant of the second agent, these two pathogenic and/or infective agents originating from the same viral strain chosen from the strains designated, respectively, POL-2 deposited with the ECACC on Jul. 22, 1992 under Accession Number V92072202 and MS7PG deposited with the ECACC on Jan. 8, 1993 under Accession Number V93010816, and from their variant strains.
摘要翻译： 包括与多发性硬化症相关的两种致病和/或感染因子的组合物，即由具有逆转录酶活性并与内源性逆转录病毒元件家族或病毒变体相关的人类病毒组成的第一药剂和第二药剂， 或来自相同病毒株的两种致病和/或感染因子，分别选自于1992年7月22日以保藏号V92072202和保藏号为V92072202的ECACC分别保藏的POL-2的菌株 1993年1月8日，ECACC以保藏号V93010816和其变体菌株。
-
公开(公告)号：USD301850S
公开(公告)日：1989-06-27
申请号：US875012
申请日：1986-06-13
-
公开(公告)号：US20100330580A1
公开(公告)日：2010-12-30
申请号：US12918126
申请日：2009-03-10
CPC分类号： C12Q1/6886 , C12Q1/686 , C12Q1/702 , C12Q2535/125 , C12Q2600/154 , C12Q2600/158
摘要： A method for in vitro diagnosis or prognosis of testicular cancer in a biological sample from a patient suspected of suffering from testicular cancer, having a step of detecting the presence or absence of methylation of CpG dinucleotides in at least one genomic DNA target sequence of the sample, the target sequence being selected from at least one of the sequences identified in SEQ ID NOS: 1 to 7 or from at least one sequence which exhibits at least 99% identity with one of the sequences identified in SEQ ID NOS: 1 to 7 and the sequences complementary thereto; to the DNA sequences and to the use thereof as a testicular cancer marker.
摘要翻译： 一种用于体外诊断或预测来自疑似患有睾丸癌的患者的生物样品中睾丸癌的方法，该方法具有检测样品中至少一个基因组DNA靶序列中CpG二核苷酸甲基化的存在或不存在的步骤 靶序列选自SEQ ID NO：1至7中鉴定的至少一个序列或至少一个与SEQ ID NO：1至7中鉴定的序列之一具有至少99％同一性的序列;以及 与之互补的序列; DNA序列及其作为睾丸癌标志物的用途。
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.027 秒)
